Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-22
2008-03-18
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S452000, C548S465000, C514S412000
Reexamination Certificate
active
07345081
ABSTRACT:
The invention provides novel inhibitors of IAP that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:X1and X2are independently O or S; L is a bond or —C(X3)—, —C(X3)NR12, —C(X3)O— wherein X3is O or S and R12is H or R1; R1is alkyl, a carbocycle, carbocycle-substituted alkyl, a heterocycle or heterocycle-substituted alkyl, wherein each is optionally substituted with halogen, hydroxyl, mercapto, carboxyl, alkyl, haloalkyl, alkoxy, alkylsulfonyl, amino, nitro, aryl and heteroaryl; R2is alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, a heterocycle or heterocyclylalkyl; R3is H or alkyl; R4and R4′are independently H, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, or heteroaralkyl wherein each is optionally substituted with halogen, hydroxyl, mercapto, carboxyl, alkyl, alkoxy, amino and nitro; R5, and R5′are each independently H or alkyl; R6is H or alkyl; and salts and solvates thereof.
REFERENCES:
patent: 4278793 (1981-07-01), Durckheimer et al.
patent: 4720484 (1988-01-01), Vincent et al.
patent: 5411942 (1995-05-01), Widmer et al.
patent: 5559209 (1996-09-01), Nishimoto
patent: 6472172 (2002-10-01), Deng et al.
patent: 6608026 (2003-08-01), Wang et al.
patent: 6992063 (2006-01-01), Shi
patent: 7041784 (2006-05-01), Wang et al.
patent: 2002/0177557 (2002-11-01), Shi
patent: 2003/0157522 (2003-08-01), Boudreault et al.
patent: 2006/0052311 (2006-03-01), Sharma et al.
patent: WO 92/01938 (1992-02-01), None
patent: WO 00/00823 (2000-01-01), None
patent: WO 00/39585 (2000-07-01), None
patent: WO 02/16402 (2002-02-01), None
patent: WO 02/16418 (2002-02-01), None
patent: WO 02/26775 (2002-04-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 02/096930 (2002-12-01), None
patent: WO 03/010184 (2003-02-01), None
patent: WO 03/086470 (2003-10-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 2004/007529 (2004-01-01), None
patent: WO 2004/017991 (2004-03-01), None
patent: WO 2004/072641 (2004-08-01), None
patent: WO 2004/106371 (2004-12-01), None
patent: WO 2005/049853 (2005-06-01), None
patent: WO 2005/097791 (2005-10-01), None
patent: WO 2006/020060 (2006-02-01), None
U.S. Appl. No. 10/364,645, filed Jul. 2, 2003, Franklin, M. et al.
U.S. Appl. No. 10/983,495, filed Aug. 11, 2004, Fairbrother, W. et al.
Arnt et al., “Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ”J. Bio. Chem. 277(46):44236-44243 (Nov. 2002).
Baktiar, et al., “Transfer of alkoxycarbonyl frpm alkyl imidazolium-2-carboxylates to benzyl alcohol, a cyclohexanone enamine and diethylamine”J. Chem. Soc. Perkin Trans. 13:329-243 (Jan. 1994).
Blass, B.E. et al., “Parallel Synthesis and Evaluation of N-(1-Phenylethyl)-5-phenyl-imidazole-2-amines as Na+/K+ ATPase inhibitors”Bioorg. Med. Chem. Lett. 10:1543-1545 (2000).
Chai et al., “Structural and Biochemical Basis of Apoptotic Activation by Smac/DIABLO”Nature406:855-862 (Aug. 2000).
Corey, E.J. et al., “(+)-1(S), 5(R), 8(S)-phenyl-2-azabicyclo [3.3.0]OCTAN-8-0L N, O-methylboronate (2) and its enantiomer, chiral chemzymes which serve as catalysts—for their own enantioselective synthesis” Tetrahedron Letters 30(41):5547-5550 (1989).
Crook et al., “An Apoptosis-Inhibiting Baculovirus Gene with a Zinc Finger-Like Motif”Journal of Virology67(4):2168-2174 (Apr. 1993).
Deveraux et al., “Endogenous Inhibitors of Caspases”J. Clin. Immuno. 19(6):388-398 (1999).
Deveraux et al., “IAPs Block Apoptotic Events Induced by Caspase-8 and Cytochrome c by Direct Inhibition of Distinct Caspases”EMBO Journal17(8):2215-2223 (1998).
Fong et al., “Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines”Genomics70:113-122 (2000).
Fulda et al., “Smac Agonists Sensitize for Apo2L/TRAIL- or Anticancer Drug-Induced Apoptosis and Induce Regression of Malignant Glioma in Vivo”Nature Medicine8(8):808-815 (Aug. 2002).
Guo et al., “Ectopic Overexpression of Second Mitochondria-Derived Activator of Caspases (Smac/DIABLO) or Cotreatment with N-Terminus of Smac/DIABLO Peptide Potentiates Epothilone B Derivative- (BMS 247550) and Apo-2L/TRAIL Induced Apoptosis”Blood99:3419-3426 (2002).
Hinds et al., “Solution Structure of a Baculoviral Inhibitor of Apoptosis (IAP) Repeat”Nat. Struct. Biol. 6:648-651 (Jul. 1999).
Hu et al., “Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo”Clin. Cancer Res9(7):2826-2836 (2003).
Keating, S.M. et al.Proceedings of SPIE:In VitoDiagnostic Instrumentation, Cohn ,G. E., Bellingham, WA pp. 128-137 (2000).
Kolb et al., “Use of a novel homogeneous fluorescent technology in high throughput screening”J Biomolecular Screening1(4):203-210 (1996).
LaCase et al., “The inhibitors of apoptosis (IAPs) and their emerging role in cancer”Oncogene17(25):3247-3259 (1998).
Lin et al., “Resistance of bone marrow-derived macrophages to apoptosis is associated with the expression of X-linked inhibitor of apoptosis protein in primary cultures of bone marrow cells”Biochemical Journal353:299-306 (2001).
Liston et al., “Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes”Nature379:349-353 (1996).
Liu et al., “Structural Basis for Binding of Smac/DIABLO to the XIAP BIR3 Domain”Nature408:1004-1008 (Dec. 2000).
Masuda et al., “Studies on mesoinic compounds. Part 11. Alkylation of 5-acylamino-1,2,3-thiadiazoles”J. Chem. Soc. Perkin. Trans. 15:1591-1595 (1981).
Sasaki et al., “Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells”Cancer Research60(20):5659-5666 (2000).
Tamm et al., “Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias”Clin. Cancer Res. 6(5):1796-1803 (2000).
Thompson, “Apoptosis in the Pathogenesis and Treatment of Disease”Science267:1456-1462 (1995).
Vucic et al., “ML-IAP, A Novel Inhibitor of Apoptosis that is Preferentially Expressed in Human Melanomas”Current Bio. 10:1359-1366 (Oct. 2000).
Vucic et al., “SMAC Negatively Regulates the Anti-apoptotic Activity of Melanoma Inhibitor of Apoptosis (ML-IAP)”The Journal of Biological Chemistry277:12275-12279 (2002).
Wu et al., “Structural Basis of IAP Recognition by Smac/DIABLO”Nature408:1008-1012 (Dec 2000).
Yang et al., “Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated smac peptide”Cancer Research63(4):831-837 (2003).
Cohen Frederick
Fairbrother Wayne
Flygare John
Keteltas Stephen Franz
Tsui Vickie Hsiao-Wei
Evans David W
Genentech Inc.
Shameem Golam M. M.
LandOfFree
Azabicyclo-octane inhibitors of IAP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azabicyclo-octane inhibitors of IAP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azabicyclo-octane inhibitors of IAP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3962243